HTR2A

5-hydroxytryptamine receptor 2A · P28223 · HTR2A on Sugi Atlas →

804,889 patent compounds predicted against HTR2A, 472,058 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Epinastine (SCHEMBL18794)	0.45	15/20
Serotonin (SCHEMBL1495)	1.00	7/20
Mianserin (SCHEMBL18020)	1.00	7/20
Prochlorperazine (SCHEMBL18429)	1.00	7/20
SCHEMBL3472	0.64	7/20
Ergotamine (SCHEMBL1483)	1.00	6/20
Amitriptyline (SCHEMBL7824)	1.00	6/20
Ergotamine (SCHEMBL8045)	0.93	6/20
Ergotamine (SCHEMBL8046)	0.93	6/20
SCHEMBL8423	0.77	5/20
SCHEMBL979	0.63	5/20
Sumatriptan (SCHEMBL1482)	1.00	4/20
Almotriptan (SCHEMBL1957)	1.00	4/20
Cyproheptadine (SCHEMBL4021)	1.00	4/20
Ketotifen (SCHEMBL4436)	1.00	4/20
Brompheniramine (SCHEMBL4814)	1.00	4/20
Ketotifen (SCHEMBL8809)	1.00	4/20
Ketotifen (SCHEMBL8810)	1.00	4/20
Fenfluramine (SCHEMBL16215)	1.00	4/20
Dexfenfluramine (SCHEMBL16706)	1.00	4/20

Clinical trials — most relevant to HTR2A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression	PHASE4	COMPLETED
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases	PHASE4	RECRUITING
Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression	PHASE1/PHASE2	RECRUITING
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder	PHASE2	RECRUITING
Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)	PHASE2	NOT_YET_RECRUITING
An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression	PHASE2	COMPLETED
Pimavanserin and Aggression and Social Cognition.	PHASE2	RECRUITING
5HT2CR Balance in Brain Connectivity in Cocaine Dependence	PHASE1/PHASE2	COMPLETED
Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept	PHASE2	COMPLETED
Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects	PHASE1	COMPLETED
The Neurobiological Effect of 5-HT2AR Modulation	PHASE1	RECRUITING
Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects	PHASE1	COMPLETED
A Brain Imaging Study to Assess the Binding of MSP-2020 to Serotonin 5-HT2A Receptors in Healthy Male Adults	PHASE1	RECRUITING
Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder	PHASE1	WITHDRAWN
Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects	PHASE1	COMPLETED
A Dose-Ranging Study of JNJ-40411813 in Healthy Male Volunteers	PHASE1	COMPLETED
Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects	PHASE1	COMPLETED
SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis	EARLY_PHASE1	UNKNOWN
Mood Effects of Serotonin Agonists: Depression	EARLY_PHASE1	RECRUITING
Epigenetic and Neurochemical Correlates of Bipolar Disorder	nan	NOT_YET_RECRUITING
Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors	nan	COMPLETED
The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers	nan	COMPLETED
Investigating the Neuropsychological Effects of 5-HT2a Antagonism	nan	RECRUITING
The Efficacy of Tianeptine Versus Pregabalin on Acute and Chronic Post Mastectomy Pain After Breast Cancer Surgery.	nan	COMPLETED
A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks	nan	COMPLETED
Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD	nan	RECRUITING
Microdosing LSD in Women With Premenstrual Disorders	nan	NOT_YET_RECRUITING
Effects of Lurasidone on Left Ventricle Systolic Functions	nan	NOT_YET_RECRUITING
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Trazodone and the Risk of Serious Adverse Events	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a HTR2A binder may also engage these)

Protein	Name	Similarity
Q5R4Q6	—	1.000	Q5R4Q6 →
P50128	—	1.000	P50128 →
P50129	—	1.000	P50129 →
Q75Z89	—	1.000	Q75Z89 →
P18599	—	1.000	P18599 →
O46635	—	1.000	O46635 →
P14842	—	1.000	P14842 →
P35363	—	0.999	P35363 →
HTR2C	5-hydroxytryptamine receptor 2C	0.991	landscape →
Q8UUG8	—	0.988	Q8UUG8 →
P34968	—	0.988	P34968 →
Q5IS66	—	0.987	Q5IS66 →
Q02152	—	0.987	Q02152 →
P08909	—	0.987	P08909 →
Q60F97	—	0.987	Q60F97 →
ADRA1A	Alpha-1A adrenergic receptor	0.986	landscape →
Q9N2A4	—	0.985	Q9N2A4 →
P18901	—	0.985	P18901 →
P56490	—	0.985	P56490 →
HTR2B	5-hydroxytryptamine receptor 2B	0.984	landscape →
P30994	—	0.983	P30994 →
P08483	—	0.982	P08483 →
P97718	—	0.982	P97718 →
Q9WU25	—	0.982	Q9WU25 →
CHRM5	Muscarinic acetylcholine receptor M5	0.981	landscape →
P08911	—	0.981	P08911 →
P42288	—	0.981	P42288 →
O02824	—	0.981	O02824 →
Q5IS98	—	0.981	Q5IS98 →
P18130	—	0.981	P18130 →